SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Zura Bio Limited (ZURA) News

Follow Zura Bio Limited (ZURA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ZURA Asset equity Sector Markets 90 days 10 Last 0.9243 Updated Oct 28, 2026, 05:30 AM UTC Open live news feed Open ZURA chart & news
M ZURA Reports Fiscal Q3 Loss Profit attributable to shareholders was -7635万美元, down 42.79% year over year. Basic EPS was -0.62美元. EQUITY | Oct 28, 2026, 05:30 AM UTC M Zura Bio Reports Third-Quarter Loss per Share EQUITY | Oct 27, 2026, 11:42 AM UTC M Zura Bio Q3 Pretax Profit USD -27.046 Million EQUITY | Oct 27, 2026, 11:32 AM UTC L Zura Bio Reports Q3 Net Income of USD -25.825 Million EARNINGS | Oct 27, 2026, 11:31 AM UTC M Zura Bio Q3 Operating Income: USD -28.773 Million EARNINGS | Oct 27, 2026, 11:31 AM UTC M Zura Bio Reports Third-Quarter 2026 Financial Results Zura Bio reported financial results for the third quarter of 2026; the supplied text is truncated before any figures or further details. EQUITY | Oct 27, 2026, 11:30 AM UTC H BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE: BKV ) rose sharply after the company announced that a subsidiary executed into a n equipment supply contract. BKV LIVE | Oct 07, 2026, 02:08 PM UTC M ZURA nears pivotal-trial readouts for IL-17/BAFF bispecific in autoimmunity ZURA says upcoming pivotal-trial data in hidradenitis suppurativa and systemic sclerosis will test a bispecific antibody targeting IL-17 and BAFF, aiming to address efficacy ceilings in autoimmune diseases. EQUITY | Sep 09, 2026, 02:59 PM UTC M ZURA advances tibulizumab dual-target bispecific in autoimmune pivotal trials ZURA is advancing a multifunctional antibody pipeline, with tibulizumab leading pivotal trials for hidradenitis suppurativa and systemic sclerosis. The bispecific targets IL-17 and BAFF for potential superior efficacy, w EQUITY | Sep 09, 2026, 02:07 PM UTC L Zura Bio to Participate in the Cantor Global Healthcare Conference Zura Bio to Participate in the Cantor Global Healthcare Conference EQUITY | Aug 31, 2026, 08:30 PM UTC L Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ: ZURA ) with a Outperform and maintains $15 price target. EQUITY | Jul 01, 2026, 01:56 PM UTC